UCB, a global biopharmaceutical company, today announced positive topline data from the BE BOLD trial assessing BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in adults with active psoriatic ...
In clinical trials, more than half of all patients treated with deucravacitinib achieved at least 20% improvement in American College of Rheumatology response criteria.
Primary endpoint showing superiority met: Bimekizumab achieved statistically significant superiority over risankizumab in reducing disease activity, as measured by the stringent ACR50 endpoint, at ...
Hosted on MSN
How long do elephants actually live?
They are large, intelligent, and remarkably social—elephants fascinate many people. With their calm demeanor, they impress at first glance. But it’s not just their appearance; their longevity is also ...
New Scientist on MSN
Inflammation might cause Alzheimer's – here's how to reduce it
Persistent inflammation in the gut, lungs and skin might lead to Alzheimer's disease, but lifestyle choices - from getting ...
Background Psoriatic disease has a complex effect on bone metabolism, resulting in both pathological bone formation and bone resorption. However, microstructural changes in cortical and trabecular ...
A 91-year-old man with a history of bladder carcinoma and left total knee arthroplasty was evaluated because of left knee pain. A culture of synovial fluid showed no growth. A diagnosis was made.
State pensioners with certain health conditions can get up to £218.40 extra per year from the Department for Work and ...
In South Africa, access to weight loss medicines like Ozempic and Mounjaro remains limited to those who can shell out a few thousand rand a month.
Opinion
South Africa: Obesity Medicines Are Needed in SA's Public Sector. Can Our Government Provide Them?
In South Africa, access to weight loss medicines like Ozempic and Mounjaro remains limited to those who can shell out a few thousand Rand a month. In the second article of a Spotlight special series, ...
Objective To present updated integrated safety analyses of bimekizumab in patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA). Methods Safety data pooled from six phase IIb/III ...
U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results